Clinical and Genetic Risk Factors Predict Atrial Fibrillation on the Basis of Hypertrophic Cardiomyopathy.

BACKGROUND

Clinical and genetic predispositions are significant in predicting atrial fibrillation (AF); however, their role in patients with hypertrophic cardiomyopathy (HCM) remains unclear. This study aims to elucidate the impact of clinical and genetic risk factors on the development of AF in patients with and without HCM.

METHODS AND RESULTS

This retrospective analysis involved data from the UK Biobank cohort. Participants were divided into 3 groups based on their validated polygenic risk score for AF: the bottom 10% as low risk, the top 10% as high risk, and the rest as intermediate risk. We assessed the incidence of AF and cardiovascular complications and analyzed its predictors, including genetic risk. We examined 1180 patients with HCM (mean age, 61.1±7.1; 63.0% men) and 476 238 participants without HCM (mean age, 57.0±8.1; 45.3% men). During the 11.6-year follow-up period, the age- and sex-adjusted AF incidence rates for the low, intermediate, and high genetic risk groups were 2.4, 3.6, and 5.4 per 100 person-years in participants with HCM and 0.2, 0.5, and 1.0 per 100 person-years in participants without HCM, respectively. Genetic risk, evaluated as a continuous variable using polygenic risk score, was a less significant predictor of AF in the HCM group (hazard ratio [HR], 1.35 [95% CI, 1.21-1.49]) than in non-HCM group (HR, 1.57 [95% CI, 1.56-1.59]; =0.005 for interaction). A high genetic risk was significantly associated with the risk of cardiovascular complications in both groups.

CONCLUSIONS

Genetic predisposition is associated with the development of AF and cardiovascular complications in people with and without HCM; this association was weaker in the HCM group.